	US 12,440,547 B2
	*Live salmonella* typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof**
James E. Galen, Eldersburg, MD (US); Thanh Pham, Baltimore, MD (US); Dacie R. Bridge, Blairsville, PA (US); Jin Yuan Wang, Silver Spring, MD (US); and Wangxue Chen, Ottawa (CA)
Assigned to University of Maryland, Baltimore, Baltimore, MD (US); and National Research Council of Canada, Ottawa (CA)
Filed by University of Maryland, Baltimore, Baltimore, MD (US); and National Research Council of Canada, Ottawa (CA)
Filed on Sep. 5, 2023, as Appl. No. 18/242,319.
Application 18/242,319 is a continuation of application No. 16/614,261, granted, now 11,744,884, issued on Sep. 5, 2023, previously published as PCT/US2018/032662, filed on May 15, 2018.
Claims priority of provisional application 62/506,078, filed on May 15, 2017.
Prior Publication US 2024/0156936 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/05 (2006.01); A61K 39/108 (2006.01); A61K 39/112 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/0275 (2013.01) [A61K 39/0266 (2013.01); A61K 39/05 (2013.01); A61K 2039/523 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01)]

18 Claims

1. A live Salmonella typhi vector that has been engineered

i) to express one or more heterologous antigens; and

ii) to overexpress a lipid A deacylase PagL, wherein the Salmonella Typhi vector is capable of increased formation and delivery of immunogenic recombinant outer membrane vesicles (rOMVs) comprising the one or more heterologous antigens.